Omega Therapeutics Inc OMGA
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if OMGA is a good fit for your portfolio.
News
-
Omega Therapeutics to Present New Preclinical Data on Epigenomic Upregulation at the American Society of Gene and Cell Therapy 27th Annual Meeting
-
Omega Therapeutics Presents New Preclinical Data at AACR 2024 Supporting the Potential of Precision Epigenomic Control
-
Omega Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Strategic Update
-
Omega Therapeutics Announces Two Poster Presentations at the American Association for Cancer Research Annual Meeting 2024
-
Omega Therapeutics stock more than doubles on Novo Nordisk obesity drug research pact
Trading Information
- Previous Close Price
- $2.35
- Day Range
- $2.26–2.40
- 52-Week Range
- $1.30–10.09
- Bid/Ask
- $2.23 / $2.49
- Market Cap
- $125.20 Mil
- Volume/Avg
- 257,466 / 413,560
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 41.02
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Omega Therapeutics Inc is a development-stage biotechnology company leveraging its proprietary epigenomic programming platform to biologically engineer a new class of programmable epigenetic medicines, known as Omega Epigenomic Controllers. Using epigenomic controllers, Omega is seeking to transform the practice of human medicine through selective and direct control of the human genome to treat and cure disease. It operates in the U.S.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 94
Comparables
Valuation
|
Metric
|
OMGA
|
CELC
|
LYEL
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | 2.23 | 2.91 | 0.84 |
Price/Sales | 41.02 | — | 4,189.19 |
Price/Cash Flow | — | — | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
OMGA
|
CELC
|
LYEL
|
|---|---|---|---|
Quick Ratio | 3.00 | 12.78 | 15.82 |
Current Ratio | 3.35 | 13.43 | 16.07 |
Interest Coverage | — | −12.43 | — |
Quick Ratio
OMGA
CELC
LYEL
Profitability
|
Metric
|
OMGA
|
CELC
|
LYEL
|
|---|---|---|---|
Return on Assets (Normalized) | −46.60% | −35.57% | −20.62% |
Return on Equity (Normalized) | −96.82% | −49.08% | −23.35% |
Return on Invested Capital (Normalized) | −51.97% | −39.21% | −24.46% |
Return on Assets
OMGA
CELC
LYEL
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Bmgplysvd | Zwhck | $554.7 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Zwmslss | Qsfmspy | $102.7 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Gxnbwmfs | Ktgkdg | $97.8 Bil | |
MRNA
| Moderna Inc | Jztcyxntf | Xjtr | $41.3 Bil | |
ARGX
| argenx SE ADR | Psdbmjyx | Qsr | $22.3 Bil | |
BNTX
| BioNTech SE ADR | Mgjsnpc | Nmsj | $21.0 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Vqdrjhlz | Mlxmdz | $18.2 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Mnpyktk | Zgncm | $15.4 Bil | |
RPRX
| Royalty Pharma PLC Class A | Kkpswyqrv | Djnck | $12.5 Bil | |
INCY
| Incyte Corp | Lrwbqxvs | Hcvmg | $11.6 Bil |